Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9851 USD | +2.61% | -7.07% | -6.18% |
Apr. 01 | Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 26 | Transcript : Quince Therapeutics, Inc. - Special Call |
Financials (USD)
Sales 2022 | - | Sales 2023 | - | Capitalization | 45.01M |
---|---|---|---|---|---|
Net income 2022 | -51M | Net income 2023 | -31M | EV / Sales 2022 | - |
Net cash position 2022 | 89.73M | Net cash position 2023 | 61.24M | EV / Sales 2023 | - |
P/E ratio 2022 |
-0.41
x | P/E ratio 2023 |
-1.25
x | Employees | 32 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 82.94% |
Latest transcript on Quince Therapeutics, Inc.
1 day | +2.61% | ||
1 week | -7.07% | ||
Current month | -7.93% | ||
1 month | -5.28% | ||
3 months | -25.93% | ||
6 months | +4.34% | ||
Current year | -6.18% |
Managers | Title | Age | Since |
---|---|---|---|
Dirk Thye
CEO | Chief Executive Officer | 54 | 22-05-18 |
Brendan Hannah
DFI | Director of Finance/CFO | 39 | 22-04-30 |
Charles Ryan
PSD | President | 60 | 23-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Una Ryan
BRD | Director/Board Member | 82 | 18-02-28 |
Luca Benatti
BRD | Director/Board Member | 63 | 23-10-22 |
Dirk Thye
CEO | Chief Executive Officer | 54 | 22-05-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 0.9851 | +2.61% | 49,304 |
24-05-02 | 0.96 | -3.36% | 105,089 |
24-05-01 | 0.9934 | -7.16% | 49,006 |
24-04-30 | 1.07 | +1.42% | 96,568 |
24-04-29 | 1.055 | -0.47% | 25,698 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-6.18% | 42.57M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- QNCX Stock